Shilpa Medicare gets USFDA nod for psoriatic arthritis drug Apremilast

Written by Ruchika Sharma Published On 2021-03-06T11:35:28+05:30 | Updated On 6 March 2021 11:38 AM IST

Shilpa Medicare gets USFDA nod for psoriatic arthritis drug Apremilast

Karnataka: Shilpa Medicare has recently announced that the company has received U.S Food and Drug Administration (USFDA) tentative approval for its abbreviated new drug application (ANDA), Apremilast Tablets, 10 mg, 20 mg, and 30 mg dated 04 Mar 2021. The ANDA was filed as 'First to File' submission on NCE -1 date to seek eligibility for 180 days exclusivity.

Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene used in the treatment of 'psoriatic arthritis' as recommended in the label approved by FDA.

According to IQVIA MAT Q2 2020 data, the US market for Apremilast Tablets, 10 mg, 20 mg, and 30 mg is approximately US $2.4 billion.

Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.

shilpa medicareshilpa medicare newsapremilast tabletsotezlapsoriatic arthritis

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751